| Breakdown | TTM | Dec 2025 | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 276.00B | 272.67B | 255.37B | 225.59B | 217.08B | 191.21B |
| Gross Profit | 168.82B | 180.92B | 164.93B | 141.04B | 130.18B | 116.14B |
| EBITDA | 73.89B | 70.22B | 61.91B | 49.19B | 44.39B | 41.24B |
| Net Income | 53.92B | 52.73B | 41.22B | 28.02B | 25.17B | 24.05B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 373.87B | 327.18B | 294.63B | 271.01B | 251.52B |
| Cash, Cash Equivalents and Short-Term Investments | 106.17B | 106.17B | 77.96B | 62.77B | 46.32B | 37.46B |
| Total Debt | 0.00 | 4.39B | 5.60B | 8.03B | 10.56B | 20.24B |
| Total Liabilities | -312.89B | 60.98B | 59.15B | 57.50B | 59.84B | 65.66B |
| Stockholders Equity | 312.89B | 311.93B | 267.07B | 234.08B | 208.42B | 183.27B |
Cash Flow | ||||||
| Free Cash Flow | 0.00 | 38.43B | 27.85B | 20.55B | 26.25B | 29.36B |
| Operating Cash Flow | 0.00 | 50.05B | 41.34B | 32.38B | 33.26B | 37.55B |
| Investing Cash Flow | 0.00 | -36.91B | -29.88B | -23.89B | -18.72B | -23.87B |
| Financing Cash Flow | 0.00 | -12.93B | -12.00B | -9.58B | -16.00B | -12.40B |
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
| ― | ₹1.27T | 23.63 | ― | 0.83% | 6.40% | 25.27% | |
| ― | ₹243.86B | 30.33 | ― | 0.66% | 4.35% | 32.89% | |
| ― | ₹108.90B | 30.15 | ― | 2.48% | -23.93% | -31.53% | |
| ― | ₹635.62B | 43.61 | ― | 1.60% | 11.17% | 17.22% | |
| ― | ₹318.91B | 41.40 | ― | 0.94% | -2.34% | 6.64% | |
| ― | ₹465.11B | 48.87 | ― | 2.04% | 6.65% | 48.47% | |
| ― | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% |
Cipla Ltd has submitted a certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018, confirming the processing of dematerialization requests for the quarter ending September 30, 2025. This announcement underscores Cipla’s compliance with regulatory requirements, ensuring that its securities are properly managed and listed on the relevant stock exchanges, thereby maintaining transparency and trust with its stakeholders.
Study Overview: Eli Lilly and Company, in collaboration with Cipla Ltd., recently completed a Phase 4 clinical study titled A 26-Week, Multicenter, Open-Label, Single-Arm, Phase 4 Study to Assess The Safety of Lyumjev in Adult Patients With Type 2 Diabetes Mellitus in India. The study aimed to evaluate the safety of insulin lispro-aabc in adults with Type 2 diabetes mellitus, a significant step in enhancing diabetes management in India.
Cipla Ltd has announced that it will release its unaudited financial results for the second quarter of the fiscal year 2026 on October 30, 2025. The company will host an earnings conference call on the same day to discuss its financial performance and address questions from stakeholders. This announcement is part of Cipla’s ongoing efforts to maintain transparency with investors and stakeholders, potentially impacting its market positioning and investor relations.
Cipla Limited has announced the allotment of 2,853 equity shares under its Employee Stock Option Scheme 2013-A and the Cipla Employee Stock Appreciation Rights Scheme 2021. This move increases the company’s issued, subscribed, and paid-up share capital to INR 1,61,55,08,148, reflecting its ongoing commitment to employee engagement and retention strategies.
Cipla Ltd announced the opening of a special window for the re-lodgement of transfer requests for physical shares, as per the SEBI regulations. This initiative, communicated through newspaper advertisements, aims to facilitate shareholders in transferring their physical shares, reflecting the company’s commitment to compliance and shareholder engagement.
Cipla Ltd has released its unaudited financial results for the quarter ended June 30, 2025, showing a revenue from continuing operations of ₹3,719 crore and a net profit of ₹316 crore. The results indicate a significant improvement in profitability compared to the previous quarter, reflecting Cipla’s robust operational performance and strategic market positioning. This financial update is crucial for stakeholders as it highlights the company’s resilience and growth potential in the competitive pharmaceutical industry.